Lymphoma, B-cell, Lymphoma, Low-grade, Non-Hodgkin's Lymphoma
Conditions
Brief summary
The purpose of this study is to look at the safety and effectiveness of ONTAK in previously treated patients with NHL.
Interventions
DRUGONTAK
Sponsors
Eisai Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathological diagnosis of low-grade (indolent), B-cell, non-Hodgkin's lymphoma. * Positive expression for CD25 of tumor cells in a lymph node biopsy as defined by greater than 20% of malignant cells staining for CD25 by standardized immunohistochemical assay. * Modified Ann Arbor Stage I, II, III or IV. * Patients must have received at least two but no more than five prior therapies. One prior therapy must have been cytotoxic chemotherapy and one prior therapy must have been monoclonal antibody therapy. Combination chemotherapy, including regimens used prior to bone marrow transplantation, will count as a single therapy for purposes of eligibility. * Patients must have bidimensionally measurable disease. * Patients must be 18 years of age or older. * An ECOG performance status of 0, 1, or 2. * Acceptable organ function defined as follows: * absolute neutrophil count (ANC) \> or = to 1,000/mm3, platelet count \> or = to 50,000/mm3, Hemoglobin \> or = to 8 g/dL; * Bilirubin \< or = to 1.5 times the upper limit of normal (ULN); * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< or = to 1.5 times the upper limit of normal; * Serum creatinine \<1.8mg/dL; * Serum albumin \> or = to 3.0 g/dL. * New York Heart Association classification of I or II and no history of poorly controlled hypertension. * Must be free of serious concurrent illness. * Female patients must meet the following criteria: * If the patient is a female of childbearing potential, she must have negative serum beta human chorionic gonadotropin (B-hCG) pregnancy test within seven days prior to study entry and must have used an effective means of contraception or have been sexually abstinent for at least four weeks prior to the negative serum pregnancy test and through to study entry. * Female patients of childbearing potential must agree to practice an effective method of birth control during the entire treatment period and for at least three weeks after their last treatment on protocol.
Exclusion criteria
* Patients with cutaneous T-cell lymphoma. * Patients previously treated with ONTAK (DAB389lL-2) or DAB486IL-2. * Inability to comply with protocol requirements for this study. * Pregnant women or lactating women who are breast feeding or women planning to become pregnant during the treatment period or three weeks after their last treatment on protocol. * Serious intercurrent medical illnesses or active infections requiring parenteral antibiotics, which would interfere with the ability of the patient to carry out the treatment program. * Sero-positive for human immunodeficiency virus (HIV) antibody. History of ongoing Hepatitis B or Hepatitis C infection. * Another malignancy or history of another cancer with less than five disease-free years (other than resected basal or squamous cell skin cancers or in situ cervical cancer). * Patients with a known hypersensitivity to ONTAK or any of its components: diphtheria toxin, interleukin-2, or excipients. * Any investigational agents within one month prior to study entry. * Prior radiation therapy within four weeks of enrollment or to the only site of evaluable disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Clinical Response: Complete Response (CR) or Partial Response (PR) at Week 24, or, in the Event of Lengthened Cycle Intervals, at the End of Cycle 8. | 24 Weeks | Complete response: achievement of a complete regression for \>4 weeks of all palpable and x-ray demonstrable disease and bone marrow disease. Partial response: response to therapy with a 75% reduction in the greatest diameters of the measurable lesions for \>4 weeks and had indeterminate bone marrow biopsy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response | From beginning of response to time of relapse | The duration of response was defined as the time interval from start of the first response (CR or PR) to the time of documented disease progression. |
| Time-to-Treatment Failure | From start of first treatment | — |
Countries
United States
Participant flow
Recruitment details
This study was recruited at 6 centers in U.S. during the period of 18-May-2000 to 12-May-2001
Participants by arm
| Arm | Count |
|---|---|
| Ontak 4-Course Group Four courses of Ontak 9 mcg/kg/day for 5 consecutive days every 21 days | 5 |
| Ontak 8-Course Group Eight courses of Ontak 9 mcg/kg/day for 5 consecutive days every 21 days | 4 |
| Total | 9 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 1 | 1 |
| Overall Study | Death | 0 | 1 |
| Overall Study | Progressive Disease | 1 | 1 |
| Overall Study | Withdrawal by Subject | 0 | 1 |
Baseline characteristics
| Characteristic | Ontak 8-Course Group | Total | Ontak 4-Course Group |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 2 Participants | 4 Participants | 2 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants | 5 Participants | 3 Participants |
| Age Continuous | 60.8 years STANDARD_DEVIATION 15.5 | 63.3 years STANDARD_DEVIATION 11.5 | 65.4 years STANDARD_DEVIATION 8.4 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 3 Participants | 8 Participants | 5 Participants |
| Region of Enrollment United States | 4 participants | 9 participants | 5 participants |
| Sex: Female, Male Female | 1 Participants | 4 Participants | 3 Participants |
| Sex: Female, Male Male | 3 Participants | 5 Participants | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 5 / 5 | 4 / 4 |
| serious Total, serious adverse events | 1 / 5 | 1 / 4 |
Outcome results
Primary
Objective Clinical Response: Complete Response (CR) or Partial Response (PR) at Week 24, or, in the Event of Lengthened Cycle Intervals, at the End of Cycle 8.
Complete response: achievement of a complete regression for \>4 weeks of all palpable and x-ray demonstrable disease and bone marrow disease. Partial response: response to therapy with a 75% reduction in the greatest diameters of the measurable lesions for \>4 weeks and had indeterminate bone marrow biopsy
Time frame: 24 Weeks
Population: Intent-to-treat
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Ontak 4-Course Group | Objective Clinical Response: Complete Response (CR) or Partial Response (PR) at Week 24, or, in the Event of Lengthened Cycle Intervals, at the End of Cycle 8. | 1 Participants |
| Ontak 8-Course Group | Objective Clinical Response: Complete Response (CR) or Partial Response (PR) at Week 24, or, in the Event of Lengthened Cycle Intervals, at the End of Cycle 8. | 1 Participants |
Secondary
Duration of Response
The duration of response was defined as the time interval from start of the first response (CR or PR) to the time of documented disease progression.
Time frame: From beginning of response to time of relapse
Population: Intent-to-treat. Please note: Data represent 1 subject in each treatment group who responded.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Ontak 4-Course Group | Duration of Response | 175 Days |
| Ontak 8-Course Group | Duration of Response | 797 Days |
Secondary
Time-to-Treatment Failure
Time frame: From start of first treatment